KKR Launches 5M Share Secondary Offering in BridgeBio, Company Gets No Proceeds
BBIO sits 68% above its 52-week low of $46.81 on light trading volume (0.4× avg).
Summary
KKR Genetic Disorder L.P. sold 5 million shares of BridgeBio in a secondary offering, with the company receiving no proceeds. The offering priced at $78.00 per share, totaling $390 million, and was oversubscribed. It closed on August 17, 2026, at a net price of $77.415 per share to KKR Genetic Disorder L.P. After the sale, KKR's beneficial ownership fell to 4.7%, and it ceased to be a 5% owner. The sale came just weeks after BridgeBio raised $934 million in preferred equity and filed a $500 million ATM, signaling continued capital activity. The offering was led by William Blair, Goldman Sachs, and KKR, and was subject to market conditions. This followed the S-3ASR shelf filed on July 24, 2026, and added selling pressure from a major existing shareholder.
Updated with an SEC SCHEDULE 13D/A filing · What changed
Updates
· SEC SCHEDULE 13D/A — The offering closed on August 17, 2026, at a net price of $77.415 per share to KKR Genetic Disorder L.P. After the sale, KKR's beneficial ownership fell to 4.7%, and it ceased to be a 5% owner.
· GlobeNewswire — The offering priced at $78.00 per share, totaling $390 million, and is oversubscribed, with closing expected August 17.
At the time of this announcement, BBIO was trading at $78.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $46.81 to $93.42. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.